Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Abivax SA ( (FR:ABVX) ).
Abivax SA reported its financial results for the fiscal year 2024, highlighting a cash position of 144.2 million euros, which will fund operations until Q4 2025. The company is advancing its phase 3 ABTECT trial for obefazimod in ulcerative colitis, with key milestones expected in 2025. Despite an increase in R&D expenses, Abivax is maintaining financial discipline while preparing for potential commercialization, marking 2025 as a pivotal year for its development.
More about Abivax SA
Abivax SA is a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases. The company is involved in the research and development of treatments, with a significant emphasis on clinical trials for conditions such as ulcerative colitis.
YTD Price Performance: 0.15%
Average Trading Volume: 972
Technical Sentiment Signal: Buy
Current Market Cap: €430.3M
For a thorough assessment of ABVX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue